Cargando…

Two Instrument Comparison of Reagents From a US FDA-Approved Assay for the Assessment of Ki-67 in High-Risk Early Breast Cancer

The objective of this study was to measure concordance of results obtained from the US Food and Drug Administration–approved Ki-67 immunohistochemistry MIB-1 pharmDx assay performed on the Dako Omnis automated staining instrument (Omnis) versus results produced from the assay reagents applied using...

Descripción completa

Detalles Bibliográficos
Autores principales:	Komforti, Miglena, Downs-Kelly, Erinn, Sapunar, Francisco, Wijayawardana, Sameera R., Gruver, Aaron M., Badve, Sunil S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Technical Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9444283/ https://www.ncbi.nlm.nih.gov/pubmed/35880975 http://dx.doi.org/10.1097/PAI.0000000000001050

Ejemplares similares

Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer
por: Crager, Michael, et al.
Publicado: (2022)

Inhibition of Urease by Disulfiram, an FDA-Approved Thiol Reagent Used in Humans
por: Díaz-Sánchez, Ángel Gabriel, et al.
Publicado: (2016)

Identification of FDA-approved Drugs Targeting Breast Cancer Stem Cells Along With Biomarkers of Sensitivity
por: Bhat-Nakshatri, Poornima, et al.
Publicado: (2013)

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
por: Nielsen, Torsten O, et al.
Publicado: (2020)

Comparative evaluation of the new FDA approved THxID™-BRAF test with high resolution melting and sanger sequencing
por: Marchant, Julie, et al.
Publicado: (2014)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)
por: Kim, Jeeyun A., et al.
Publicado: (2021)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Ki-67 gene expression
por: Uxa, Sigrid, et al.
Publicado: (2021)

US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives
por: Wang, Shawn Shouye, et al.
Publicado: (2021)

External quality assessment (EQA) program for the immunohistochemical detection of ER, PR and Ki-67 in breast cancer: results of an interlaboratory reproducibility ring study in China
por: Pu, Tianjie, et al.
Publicado: (2019)

To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
por: Di Rosa, Francesca, et al.
Publicado: (2021)

LibKiSAO: a Java library for Querying KiSAO
por: Zhukova, Anna, et al.
Publicado: (2012)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Educational Case: Ductal Carcinoma In Situ (DCIS)
por: Komforti, Miglena K., et al.
Publicado: (2019)

Use of surrogate outcomes in US FDA drug approvals, 2003–2012: a survey
por: Yu, Tsung, et al.
Publicado: (2015)

A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma
por: Hsu, Fu-Shun, et al.
Publicado: (2017)

Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials
por: Kanapuru, Bindu, et al.
Publicado: (2022)

Corrigendum: To Ki or Not to Ki: Re-Evaluating the Use and Potentials of Ki-67 for T Cell Analysis
por: Di Rosa, Francesca, et al.
Publicado: (2021)

The intrinsically disorderly story of Ki-67
por: Remnant, Lucy, et al.
Publicado: (2021)

Sebaceous carcinoma in situ as a concept and diagnostic entity
por: Komforti, Miglena K., et al.
Publicado: (2017)

Benign Endocervical Polyp with Heterologous Elements in a 42-year-old Female: Report of a Case
por: Komforti, Miglena K, et al.
Publicado: (2019)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

FDA approved vaccines for monkeypox: Current eminence
por: Chopra, Hitesh, et al.
Publicado: (2022)

Older U.S. Adults With Nocturia Often Cannot Use the Only FDA-Approved Drugs for the Condition
por: Johnson, Theodore, et al.
Publicado: (2020)

Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies
por: Fasanella, S, et al.
Publicado: (2011)

Immunolocalization of Ki-67 in different periodontal conditions
por: Preethi, Penubolu Lakshmi, et al.
Publicado: (2014)

Cholesterol granuloma of the breast: A case report
por: Letter, Haley, et al.
Publicado: (2023)

Quantum Dots-Based Quantitative and In Situ Multiple Imaging on Ki67 and Cytokeratin to Improve Ki67 Assessment in Breast Cancer
por: Yuan, Jing Ping, et al.
Publicado: (2015)

ki67 nuclei detection and ki67-index estimation: a novel automatic approach based on human vision modeling
por: Barricelli, Barbara Rita, et al.
Publicado: (2019)

Independent Clinical Validation of the Automated Ki67 Scoring Guideline from the International Ki67 in Breast Cancer Working Group
por: Boyaci, Ceren, et al.
Publicado: (2021)

Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry
por: Selmani, Zohair, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_k4cfi1olsficnipeercsi0objb